ArticleCureus2025
The Long-Term Impact of Lorazepam on Catatonia Recurrence in Patients With Bipolar Disorder.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCatatonia is a complex syndrome characterized by behavioral and psychomotor abnormalities and is commonly associated with various medical and psychiatric conditions including schizophrenia, bipolar disorder, depression, stroke, and encephalitis. Lorazepam is widely considered the first-line treatment for catatonia, but the drug's effectiveness in preventing recurrence remains unclear. This study examines whether lorazepam reduces the risk of recurrent catatonia in patients with bipolar disorder. Methods: We conducted a retrospective cohort study using the TriNetX database, including patients who were diagnosed with bipolar disorder and catatonia between 2000 and 2024. Patients were divided into two groups: those treated with lorazepam (n = 15,674) and those who did not receive lorazepam (n = 12,045). Kaplan-Meier survival analysis and hazard ratios were used to assess recurrence risk and long-term outcomes. Results: Overall, the catatonia recurrence rate was similar between groups (p = 0.086). However, the group that did not receive lorazepam had a statistically significantly fewer total number of recurrent episodes of catatonia than the lorazepam treatment group (p = 0.005). Additionally, Kaplan-Meier analysis showed a significantly higher survival probability in the no lorazepam group (p = 0.011), indicating a longer duration of time before recurrence in this cohort. Conclusion: Lorazepam effectively treats catatonia acutely but does not significantly reduce the risk of recurrence compared to other management options. Future studies should explore individualized treatment approaches to optimize catatonia management for patients with bipolar disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.